IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFβ Release
Author(s) -
Julia Siede,
Anja Fröhlich,
Angeliki Datsi,
Ahmed N. Hegazy,
Domonkos V. Varga,
Vivien Holecska,
Hirohisa Saito,
Susumu Nakae,
Max Löhning
Publication year - 2016
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0161507
Subject(s) - foxp3 , homing (biology) , microbiology and biotechnology , chemokine , receptor , immunology , biology , chemokine receptor , t cell , population , inflammation , immune system , medicine , ecology , biochemistry , environmental health
Immunomodulatory Foxp3 + regulatory T cells (Tregs) form a heterogeneous population consisting of subsets with different activation states, migratory properties and suppressive functions. Recently, expression of the IL-33 receptor ST2 was shown on Tregs in inflammatory settings. Here we report that ST2 expression identifies highly activated Tregs in mice even under homeostatic conditions. ST2 + Tregs preferentially accumulate at non-lymphoid sites, likely mediated by their high expression of several chemokine receptors facilitating tissue homing. ST2 + Tregs exhibit a Th2-biased character, expressing GATA-3 and producing the Th2 cytokines IL-5 and IL-13 –especially in response to IL-33. Yet, IL-33 is dispensable for the generation and maintenance of these cells in vivo . Furthermore, ST2 + Tregs are superior to ST2 − Tregs in suppressing CD4 + T cell proliferation in vitro independent of IL-33. This higher suppressive capacity is partially mediated by enhanced production and activation of the anti-inflammatory cytokines IL-10 and TGFβ. Thus, ST2 expression identifies a highly activated, strongly suppressive Treg subset preferentially located in non-lymphoid tissues. Here ST2 + Tregs may be well positioned to immediately react to IL-33 alarm signals. Their specific properties may render ST2 + Tregs useful targets for immunomodulatory therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom